GB2601755A — Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes

USPTO Abstract

A cannabidiol (CBD) preparation for use in the treatment of seizures associated with epilepsy in patients who are concurrently taking bivaracetam is provided wherein the dose of brivaracetam is lowered. Preferably, the dose of cannabidiol is lowered. The seizures associated with epilepsy are preferably atonic, tonic, tonic-clonic seizures and focal seizures with secondary generalisation. Preferably the CBD is in the form of a highly purified extract of cannabis which comprises at least 95% (w/w) CBD, less than 0.15% tetrahydrocannabinol (THC), and up to 1% cannabidivarin (CBDV). The CBD may be present as a synthetic compound. The CBD is preferably used in combination with one or more concomitant anti-epileptic drugs (AEDs) selected from the group consisting of: clobazam, lamotrigine, lacosamide, rufinamide, levetiracetam, diazepam, felbamate and clonazepam. Preferably the dose of CBD is below 50mg/kg/day and preferably greater than 5mg/kg/day. The epilepsy may be Lannox-Gastaut syndrome, myoclonic absence epilepsy, tuberous sclerosis complex, Dravet syndrome, Doose syndrome, Jeavons syndrome, CDKL5, Dup15q, neuronal ceroid lipofuscinoses (NCL) and brain abnormalities.